

Product Datasheet

B7-1/CD80 Antibody (IDEC-114 (Galiximab)) - Azide and BSA Free **NBP2-81099-0.2mg**

Unit Size: 0.2 mg

Store at 4C for up to 3 months. For longer storage, aliquot and store at -20C.

www.novusbio.com



technical@novusbio.com

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NBP2-81099

Updated 9/9/2025 v.20.1

Earn rewards for product reviews and publications.

Submit a publication at www.novusbio.com/publications

Submit a review at www.novusbio.com/reviews/destination/NBP2-81099



NBP2-81099-0.2mg

B7-1/CD80 Antibody (IDEC-114 (Galiximab)) - Azide and BSA Free

Product Information	
Unit Size	0.2 mg
Concentration	1 mg/ml
Storage	Store at 4C for up to 3 months. For longer storage, aliquot and store at -20C.
Clonality	Monoclonal
Clone	IDEC-114 (Galiximab)
Preservative	0.02% Proclin 300
Isotype	IgG1 Lambda
Purity	Protein A purified
Buffer	PBS

Product Description	
Description	Novus Biologicals Human B7-1/CD80 Antibody (IDEC-114 (Galiximab)) - Azide and BSA Free (NBP2-81099) is a recombinant monoclonal antibody validated for use in IHC, WB, ELISA, Flow and IP. All Novus Biologicals antibodies are covered by our 100% guarantee.
Host	Human
Gene ID	941
Gene Symbol	CD80
Species	Human
Specificity/Sensitivity	Galiximab is a primatized mAb which consists of human constant and primate (cynomolgus macaque) variable regions and binds specifically to B7-1/CD80. B7-1/CD80 is a surface glycoprotein and a member of the B7 family of costimulatory molecules. B7-1/CD80 antigen regulates T cell activation (through interacting with CD28 or CD152) and is expressed transiently in antigen-presenting cells, T cells and normal B cells, and expressed constitutively on various subtypes of B-cell lymphomas.
Immunogen	Galiximab was prepared by immunizing cynomolgus monkeys with recombinant B7-1/CD80 antigen. The variable regions of the light and heavy chains were then cloned by being incorporated into a cassette vector (N5LG1) containing human constant region genes and subsequently transfected into the Dg44 CHO cell line (Hariharan K, 2013)

Product Application Details	
Applications	Western Blot, ELISA, Flow Cytometry, Functional, Immunohistochemistry, Immunoprecipitation, Block/Neutralize
Recommended Dilutions	Western Blot, Flow Cytometry, ELISA, Immunohistochemistry, Immunoprecipitation, Functional, Block/Neutralize
Application Notes	Galiximab acts to decrease in cell proliferation, inhibition of the constitutively active NF-kappaB pathway, increase in apoptosis and ADCC against various B-cell lymphoma cell lines. Galiximab affects CD28 and CD152 interactions with CD80. This antibody can also be used for FC, WB, ELISA, IP and IHC.





Novus Biologicals USA

10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Products Related to NBP2-81099-0.2mg

NBP2-33376H	Blue Marker Antibody (6F4-F6) [HRP]
G-102-C	Goat anti-Human IgG Secondary Antibody [Unconjugated]
NB7446	Goat anti-Human IgG Fc Secondary Antibody
NBP2-26578	Recombinant Mouse B7-1/CD80 Protein

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP2-81099

Earn gift cards/discounts by submitting a publication using this product:
www.novusbio.com/publications

